POZEN — Merger or Acquisition (September 2015)
11 slides from POZEN's merger presentation, Sep 28, 2015
Slide 1: Strategic Rationale and Vision for Aralez Pharmaceuticals
“Strategic Rationale and Vision for Aralez Pharmaceuticals” September 2015
Slide 2: Forward-looking statements
This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equit
Slide 3: A Transformational Combination
A Transformational Combination Strong Management with History of Success Diversified, Growing Revenue Base with North American Focus Strong Balance Sheet & Financial Position Irish Domicile Offers Financial & Competitive Advantage $150M at close ($75m equity/$75m convertible note) $200M committed cr
Slide 4: POZEN is a US specialty pharmaceutical company
POZEN is a US specialty pharmaceutical company that has developed multiple novel combination therapies for pain and cardiovascular diseases YOSPRALA™: Combination of delayed-release aspirin and immediate-release omeprazole for the secondary prevention of heart attack and stroke Awaiting FDA approval
Slide 5: YOSPRALA: Significant Commercial Opportunity
YOSPRALA: Significant Commercial Opportunity YOSPRALA is a unique formulation of delayed-release aspirin and immediate-release omeprazole for the secondary prevention of heart attack and stroke Market Opportunity ~24 MM* secondary prevention patients in US 70% take aspirin** Over 40% of physicians p
Slide 6: YOSPRALA Update
YOSPRALA API Aspirin Manufacturer Status YOSPRALA API primary aspirin manufacturer executing against its action plan to address FDA issues: will be subject to FDA re-inspection Steps also being taken to qualify a second supplier of aspirin API Prelaunch Preparations Scaling up and building out comme
Slide 7: Tribute: Compelling Canadian Growth Story
Tribute: Compelling Canadian Growth Story Tribute is a Canadian specialty pharmaceutical company Sales force of 28 sales representatives across Canada 20 primary care targeting PCPs/GPs, neurologists & dermatologists 8 specialty care targeting pain, GI specialists and others Acquired Medical Futures
Slide 8: Aralez – Strong Projected Revenue Growth
Aralez – Strong Projected Revenue Growth* $75M equity Robust balance sheet and demonstrated access to capital $75M convertible debt 2.5% with 32.5% premium $200M credit facility For future acquisitions * Figures reflect the addition of standalone projections and do not include any synergies or chang
Slide 9: The Aralez Growth Strategy & Priorities
The Aralez Growth Strategy & Priorities Maximize the value of expanded portfolio & geographic footprint Build around a cardiovascular-based, North American-focused portfolio Aggressive approach to CD&L and M&A to drive growth supported by new platform Leverage platform for growth with tax-efficient
Slide 10: Our Near Term Priorities
Advance YOSPRALA to submission and approval Focus on YOSPRALA prelaunch preparations & execute commercialization strategy Successfully close the Tribute Pharmaceuticals merger in the 4Q15 S4 remains subject to SEC review; In the process of responding to the SEC’s comments Finalize S-4 and go effecti
Slide 11: Strategic Rationale and Vision for Aralez Pharmaceuticals
“Strategic Rationale and Vision for Aralez Pharmaceuticals” September 2015